OBJECTIVES: To describe the extent to which nursing homes engaged families in antipsychotic initiation decisions in the year before surveyor guidance revisions were implemented. DESIGN: Mixed-methods study based on semistructured interviews. SETTING: U.S. nursing homes (N = 20) from five CMS regions (III, IV, VI, VIII, IX). PARTICIPANTS: Family members of nursing home residents (N = 41). MEASUREMENTS: Family member responses to closedand open-ended questions regarding involvement in resident care and antipsychotic initiation. Two researchers used a content analytical approach to code open responses to themes of family involvement in behavior management, decision-making, knowledge of risks and benefits, and informed consent. RESULTS: Fifty-four percent of family members felt highly involved in decisions about behavior management. Forty-two percent recalled being asked how to manage resident behavior without medication, and 17% recalled receipt of information about antipsychotic risks and benefits. Sixty-six percent felt highly involved in the process of initiating antipsychotic medication; 24% reported being asked for input into the antipsychotic initiation decision and knowing before the antipsychotic was started. CONCLUSION: Under existing federal regulations but before guidance revisions were implemented in 2013, more than 40% of families reported being involved in nonpharmacological behavior management of family members, but fewer than one in four reported being involved throughout the entire antipsychotic prescribing process. Interventions that standardize family engagement and promote adherence to existing federal regulations are needed. This discussion builds on these findings to weigh the policy options of greater enforcement of existing regulations versus enactment of new legislation to address this challenging issue. J Am Geriatr Soc 65:59-65, 2017.
D
ementia is a common progressive neurological disease that affects approximately 25 million people globally, 1 more than 5 million Americans aged 65 and older (11% of the older adult population), 2 and more than half of all nursing home residents in the United States. 3 Characterized by a progressive decline in cognitive and functional abilities, 4 behavioral and psychological symptoms of dementia (BPSDs) are common and include verbal and physical aggression; agitation; restlessness; wandering; inappropriate behaviors; psychoses such as delusions, hallucinations, and delirium; and depression. 5, 6 The management of BPSDs in nursing homes has been controversial because of the high prevalence of off-label use of antipsychotics. Antipsychotics provide only mild to moderate benefit in treating BPSDs 7 while conferring greater risk of stroke and death. 8, 9 Prior concerns about the overuse of unnecessary medications in nursing home residents led Congress to pass the Nursing Home Reform Act, 10 which called for nursing home residents to be free from chemical restraints. Prior legislative and regulatory efforts aimed at limiting antipsychotic use in nursing homes had mixed and limited effects. Although legislation initially decreased antipsychotic use, 11 there has been a slow rise over the following decades, 12 prompting a report by the Inspector General of the U.S. Department of Health and Human Services in 2011 that found that more than 83% of all Medicare claims for antipsychotics in nursing homes were for off-label uses. 13 Efforts to respond to congressional pressure and concern about this ongoing issue included proposals for new federal and state legislation for informed consent for antipsychotic use 14 and strengthening of the surveyor interpretative guidance used to enforce existing regulations. 15 Specifically, the Centers for Medicare and Medicaid Services (CMS) updated the State Operations Manual (SOM) in 2013, including nursing home interpretive guidance, to make CMS's expectations on antipsychotic use even more explicit. The SOM states that antipsychotic medications "may be considered for elderly residents with dementia but only after medical, physical, functional, psychological, emotional psychiatric, social and environmental causes have been identified and addressed," and must be "prescribed at the lowest possible dosage for the shortest period of time and are subject to gradual dose reduction and re-review." 16 Toward this end, the CMS revised guidance requires nursing homes to contact (and document attempts to contact) family members or representatives to help understand potential causes of behavioral distress to help guide nonpharmacological interventions; to involve them in the development of the resident's care plan; and to inform them of the benefits and risks of pharmacological treatment strategies, expected course of treatment, expected duration of medication use, what individualized approaches are to be used, plans to evaluate treatment effects, and alternatives to psychopharmacological medication. The extent to which these existing regulations have resulted in meaningful family involvement in antipsychotic decision-making is unclear. Furthermore, experts in decision-making argue that, for residents lacking decision-making capacity, 17 family should provide informed consent.
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The current study was designed to focus attention on the debate regarding the need for greater enforcement of existing regulations versus the need for new informed consent legislation by describing the extent to which nursing homes engaged families in antipsychotic initiation decisions in the year before surveyor guidance revisions were implemented. In the context of a larger study exploring antipsychotic use in nursing homes, semistructured interviews were conducted with family members of nursing home residents with dementia regarding antipsychotic medication initiation. The data collection period coincided with the year before the changes to the SOM, providing unique and detailed contextual information to inform the ongoing policy debate. The study's purpose is to illustrate the extent to which nursing homes engaged family members in issues relating to antipsychotic prescribing for residents with dementia and to describe family members' suggestions for improving the engagement process.
METHODS

Setting and Study Sample
A mixed-methods analysis was conducted of qualitative and quantitative data derived from a larger study examining the rationales provided by providers and family members for antipsychotic medication use in nursing home residents with dementia. Details of the parent study and the sampling strategy are described elsewhere. 19 Briefly, between February and July 2012, a sample of NH residents with dementia who had been or were being treated with antipsychotics were identified. The goal was to identify at least 200 residents residing in at least 25 NHs in five states across the continental United States. One state was selected from each of five CMS Regions (III (MidAtlantic), IV (Southeast), VI (South Central), VIII (Mountain), and IX (Southwest)). To identify a diverse and representative sample of facilities, nursing homes were identified from each state based on Minimum Data Set (MDS) 3.0 data from January 2011 to September 2011 and Nursing Home Compare ratings in October 2011. Eligible facilities had 50 or more beds and six or more residents with dementia taking antipsychotic medication based on MDS data. Five nursing homes were randomly selected from one state within each region from pools stratified according to facility size and tertile of antipsychotic use prevalence. 19 One state had six nursing homes, for a total of 26 facilities.
In each of the 26 facilities, on-site visits solely related to this project were conducted regarding the care of residents prescribed antipsychotics; these visits were not regulatory site visits. Eight residents were selected at each facility, including six residents randomly selected for inclusion with a dementia diagnosis and no concomitant diagnosis of Huntington's disease, Tourette's syndrome, or schizophrenia; the facility's Director of Nursing identified two additional residents for whom a gradual antipsychotic dose reduction had been attempted. From the resulting sample of 204 residents, nursing home staff identified a convenience sample of family or legal representatives (defined as the healthcare proxy or known family member; referred to as "family members" hereafter) willing to answer questions related to the resident's antipsychotic use. An attempt was made to interview two family members at each facility. Six facilities provided no family interviews, two facilities provided one interview, three facilities provided three interviews, and the remaining 15 provided the targeted two family interviews. The final sample included 41 interviews from 20 nursing homes.
Semistructured Interviews
An interdisciplinary research team with expertise in geriatric medicine, nursing home care, qualitative methods, nursing home regulation, and medication safety developed interview guides for nursing home stakeholders (including healthcare team members and family members) using an iterative process in which members of the team reviewed drafts, and changes were made in response to feedback from team members and the funder (CMS). Interview guides were piloted with family members from a nonparticipating nursing home. 19 
Data collection and interview instruments included
closed-and open-ended questions aimed at eliciting descriptions of family member's perceptions about why the resident was started on an antipsychotic medication. Questions addressed the family members' involvement in understanding and managing problematic behaviors, awareness of antipsychotic initiation, involvement in the antipsychotic initiation decision-making, whether information was provided about the risks and benefits, and whether permission was requested (Table 1) .
Seven registered nurses who were Surveyor Minimum Qualification Test-qualified surveyors conducted the interviews between February and July 2012. Each had at least 4 years of surveying experience and was trained in research interview and data collection techniques relevant to this study. The trainings introduced the field protocol for subject engagement, data collection, and interviewing developed for this project. Multiple live trainings were conducted on all aspects of the protocol, including sessions on research interview methods with a qualitative interview expert (CL) to standardize interview techniques and procedures. This involved practice interviews with CL that included real-time feedback on interviewing techniques, probing, pacing, and answer restating before note taking. Before data collection, all field protocol procedures and interviews were pilot tested in a nonstudy NH, where the interviews were audio-recorded. Pilot interviews lasted approximately 30-40 minutes, and CL reviewed all recordings for adherence to the protocol and provided individual feedback to each interviewer. Throughout the course of the study, monthly conference calls were conducted with interviewers to review protocol procedures, troubleshoot challenges, and standardize approaches to solutions.
After completion of the pilot testing, one-on-one interviews conducted at study NHs were not audio-recorded because of concern about respondents' openness to answering questions. Interviewers captured responses to closed-and open-ended questions in real time on the interview guides, with verbatim responses written for openended questions. When possible, in-person interviews were conducted at the nursing homes during the on-site visits; otherwise, interviews with family members were conducted over the telephone.
Data Analysis
Quantitative Data Analysis
Descriptive statistics were used to enumerate the responses to the open-ended questions that asked for yes, no, or unsure responses in addition to open explanations (Table 1) . Responses to close-ended questions were also enumerated using 10-point Likert scales (1 = not at all, 10 = very). Responses from 1 to 3 indicated low, 4-6 moderate, and 7-9 high levels of involvement and satisfaction.
Qualitative Data Analysis
Responses to open-ended interview questions were coded using directed content analytical techniques. The domains were defined a priori based on the 2013 CMS SOM revisions, 16 which state that, for residents with dementia, nursing home antipsychotic prescribing should (Table 1) involve family members to help nursing home staff understand current and prior behavioral patterns, inform family of risks and benefits of pharmacological and nonpharmacological interventions, involve family in the decision-making process, and solicit informed consent from families (in states with relevant laws). Two research team members (JT, KP) coded responses independently, and a third team member (CL) reviewed disputed responses, which were reconciled according to consensus until 100% agreement was reached.
This study was conducted under the direction and authority of the CMS Survey and Certification Group. A letter from CMS introducing the study was provided to each nursing home. Exemption was obtained from the University of Massachusetts Medical School institutional review board.
RESULTS
Of the final sample of 41 interviews, 66% of family member respondents were female, and 51% were aged 60 and older. Seventeen percent were spouses, 51% were children, 7% were siblings, and the remaining 25% were other family or nonfamily respondents. All but two were family members, and all but three described themselves as the resident's healthcare proxy.
Quantitative Results
Two questions addressed family involvement with behavior management (Table 1) . Responses indicate that fortytwo percent (n = 17) reported being asked about residentspecific techniques for behavioral management without medication, and 54% (n = 22) felt highly involved in decisions about staff response to behaviors.
Although 66% (n = 27) of families reported being highly involved and satisfied with their level of involvement in the antipsychotic decision-making process, the actual types of involvement varied in response to different questions. Fifty-six percent (n = 23) reported that they knew about the plan for antipsychotics before initiation, and 49% (n = 20) reported having "a say" in the decision, but only 24% (n = 10) reported being involved throughout the entire process, which included being asked for input about the decision to initiate the antipsychotic, having a say in whether it was initiated, and knowing about the antipsychotic before it was started.
Reports of receiving information about risks and benefits of antipsychotic medications were uncommon. When asked, "What kind of information were you given about (antipsychotic) medication?" 12% (n = 5) of family members specifically recalled getting no information, 12% (n = 5) reported getting only risk information, 12% (n = 5) reported getting only benefit information, and 29% (n = 12) were unsure. The remainder provided no response.
When asked, "Were you asked permission for (your family member) to receive this medication?" 56% (n = 23) reported that they were asked for permission before the antipsychotic was initiated, 17% (n = 7) reported that they were not asked for permission, 12% (n = 5) were unsure, and 14% (n = 6) provided no response.
Qualitative Results
Family Involvement in Behavior Management and Decision-Making
Although the quantitative results indicate that 42% or family members reported being asked about how to manage resident behaviors without medication, some family members reported wanting more opportunity to exchange information with staff. At least six family members wanted a chance for greater communication and involvement, and two wanted more information about medications and their alternatives. One family member noted that there was "no concrete discussion about alternative approaches to management of behaviors." Another family member indicated that, although they did not want their loved one taking antipsychotic medication, they did not know about any other options: "No one has asked for my suggestions, but I wouldn't know what to tell them." Several commented that enhanced communication is needed: "Call me; let me know what is going on." A theme that emerged called for an increase in communication regarding decision-making. As one family member commented, "They need to make more of an effort. They need to call." Even those who described themselves as very involved recognized a need for improvement: "(I wish the nursing home) would allow me to be more involved in the decisions about medication administration before it's prescribed."
Antipsychotic Risks and Benefits
From responses to open-ended questions, benefits that family members described included "calming," "alleviate the agitation," and "leveling her out." Risks that family members described included "shaking" and nonspecific responses such as "the side effects." None reported that the nursing homes told them about Food and Drug Administration black box warnings such as death or stroke. Family members communicated a strong desire for more information: "They did not tell me what the medication was or (what it was) for," and "They don't have people there to call you and inform you about drugs, possible dangers of taking it."
Permission for Antipsychotic Initiation and Informed Consent
Although 56% of families recalled giving permission for antipsychotic initiation, responses to open-ended questions suggest that some trusted physicians and might not have felt a need to give permission. Specifically, some family members had a hands-off, "doctor knows best about medications" attitude toward the antipsychotic decision. These comments included statements like: "I don't know (why an antipsychotic was prescribed); the doctor knows better," and "I have to trust and respect their decisions," reported by 29% (n = 12), which seemed consistent with reports that family members were "satisfied" with the decision-making process and that they had been kept informed and involved (n = 27).
DISCUSSION
This study provides a unique evaluation of family members' perspectives regarding engagement with nursing homes during the decision-making process regarding antipsychotic prescribing. Despite long-standing federal regulations for family involvement in antipsychotic decision-making, these findings suggest that family members were not adequately included in the resident care planning process in the period before the new SOM guidance was implemented.
These findings are in agreement with a previous report by the Office of the Inspector General. 20 Of 375 randomly selected nursing facility records of residents who received atypical antipsychotics, geriatric psychiatrists found that 91% lacked evidence that the resident, resident's family, or resident's legal representative participated in care planning, and 59% lacked documentation as to why there was no participation. This study extends these findings by demonstrating that, even when family members are involved in some capacity with the care-planning process, they may not be asked to help with managing behaviors nonpharmacologically or given the information necessary to provide informed consent for antipsychotic medication use.
Nursing homes may be hesitant to ask family members to help implement nonpharmacological alternatives to managing BPSDs. Perceived barriers to implementation of nonpharmacological approaches include lack of time, low staff-to-resident ratios, high staff turnover, and the perceived unpredictable and potentially short-term effectiveness of the effort. 21 A culture of prescribing that uses antipsychotics to control nursing home residents with BPSDs as first-line treatment has been described. 22 Residents admitted to nursing homes that prescribe more antipsychotics have a greater likelihood of being prescribed antipsychotics after entering the nursing home. 23 One hope has been that regulatory and legislative changes would motivate nursing homes to move from a culture of prescribing to one of holistic, resident-centered care that actively seeks resident and family involvement and ensures that family members and healthcare proxies are able to make informed decisions and provide consent in the care planning process, but the effect of regulations and informed consent legislation about antipsychotic use in nursing homes has not been studied, to the knowledge of the authors.
There is currently discussion in policy circles regarding the need for informed consent legislation at the state and federal levels. Questions related to determining legal competence and informed consent are determined locally (state law). 14 Table 2 shows that states with more-stringent informed consent laws than proposed federal legislation 14 have two characteristics in common: an explicit definition of informed consent and affirmation that nursing home residents have the right to informed consent for medical treatment, and a requirement for proxy decision-maker involvement when the resident is deemed incompetent. Attempts to pass federal legislation to require informed consent for antipsychotic medications in all nursing homes have been unsuccessful. The most-recent attempt did not pass in the 112th Congress. 24 Barriers that industry and provider groups have raised include the increased workload and nursing home burden without additional reimbursement, lack of provider availability to interact with families in a timely manner, and challenges of locating family members and legal representatives in a timely manner when medications are urgently needed. Although many of these challenges could be addressed in regulatory language, the potential negative unintended consequences of such legislation could be that nursing home staff will feel pressured to "check the box" and ensure paper compliance, without families having a meaningful conversation with providers about the risks and benefits of the medication, nonpharmacological alternatives, monitoring, target symptoms, and endpoints for reevaluation of the therapy. Furthermore, the requirements for these elements of the conversation are already in the interpretive guidance, 16 although they are not referred to as "informed consent." If state surveyors enforced these requirements, residents and families would have a better understanding of the risks and benefits of antipsychotic medication use in dementia and could make informed choices. Without proper enforcement, the extent to which any new legislation on informed consent would be effective in reducing antipsychotic use in nursing homes remains unclear.
These findings should be considered in the context of several limitations. First, the study's convenience sample included family members who were involved in the resident's care; coupled with likely social desirability bias, 25 the data may overestimate the level of family involvement in antipsychotic prescribing. Second, interviews were not audio-recorded because of privacy concerns. Study nurses transcribed responses in real time as they conducted the interviews. The quotations included must be considered paraphrases that characterize the general sentiments of responses. Finally, it was not possible to determine the amount of time a resident was cared for in a facility. Recall bias is possible because it was not possible to ascertain the time elapsed between conversations between family and nursing home staff regarding antipsychotic initiation and the interviews. Nevertheless, because standard practice calls for ongoing care plan meetings between families and NH staff at least every 90 days, concern about recall bias is somewhat mitigated because there should be recent antipsychotic-related conversations about residents regardless of their length of stay in the nursing facility (https://www.medicare.gov/what-medicare-covers/ part-a/care-plan-in-nursing-home.html).
These findings demonstrate the need for enhanced enforcement of current guidance for resident and family involvement in resident care planning. Before the changes in the SOM and national initiatives to reduce antipsychotic use in nursing homes, family members were not fully engaged in decision-making regarding antipsychotic initiation in nursing homes. These findings support the need for shared decision-making models rather than paternalistic (doctor knows best) approaches to off-label prescribing of antipsychotics with limited efficacy and known risks.
There is evidence that families can be a valuable resource for understanding a resident's lifelong habits, preferences for everyday routines, and personality characteristics, and this detailed knowledge can inform selection of effective nonpharmacological approaches to BPSDs. 26, 27 Nonpharmacological interventions show promise for treating BPSDs and lowering antipsychotic use in nursing homes. [28] [29] [30] In 2011, CMS established the National Partnership to Improve Dementia Care in Nursing Homes, a public-private partnership dedicated to reducing antipsychotic use. 31 The Partnership encourages resident and family involvement in care planning. Early findings note a decrease in antipsychotic use nationally for long-stay nursing home residents of 21.8% (from 23.9% to 18.7%) from Quarter 4, 2011, through Quarter 1, 2015. 32 Advocates remain concerned that surveyors are not enforcing regulations consistently or citing deficiencies at the appropriate scope and severity. 31, 33 CMS mandated 3 hours of surveyor training to help surveyors better recognize and cite deficient practices related to dementia care and noncompliance with federal regulations and to take appropriate enforcement action in those cases. The extent to which reductions in antipsychotic use realized with recent policy changes will be sustained in the absence of adequate state and federal enforcement is unknown and deserves further study. 
